| Name | Exendin-4 |
| Description | Exendin-4 (Exenatide) is a glucagon-like peptide-1 receptor (GLP-1) agonist (IC50: 3.22 nM). Exenatide is a 39 amino acid peptide. Compared to GLP-1, exenatide has a longer half-life of 2.4 hours. |
| In vitro | In HUVECs, exendin-4 dose-dependently significantly increases NO production, eNOS phosphorylation and GTPCH1 level[2]. Exendin-4 shows cytotoxic effects to MCF-7 breast cancer cells (IC50 5 μM) at 48 hours [3]. |
| In vivo | In ob/ob mice, the treatment of exendin-4 improve serum ALT and reduce serum glucose, insulin levels and calculated HOMA scores compared with control. In the final 4 weeks of the study period, exendin-4-treated ob/ob mice sustain an obvious reduction in the net weight gain[4]. Animals treated with exendin-4 have more pyknotic nuclei, more pancreatic acinar inflammation and weigh significantly less than control rats[5]. Exenatide leads to dose-dependent relaxation of rat thoracic aorta, which is evoked via the GLP-1 receptor and is mediated mainly by H2S but also by CO and NO[6]. |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (0.48 mM), Sonication is recommended.
DMSO : 10 mM, Sonication is recommended.
H2O : 1.23 mg/mL (0.29 mM), Sonication and heating are recommended.
|
| Keywords | GlucagonReceptor | glucagon-like peptide-1 receptor | Glucagon Receptor | Exendin-4 | Exendin4 | Exendin 4 | 141732-76-5 |
| Inhibitors Related | PF-06882961 Tris | L-168049 | PF-06882961 | Glucagon (1-29), bovine, human, porcine hydrochloride | (S, R)-LSN 3318839 | NNC 92-1687 | Adomeglivant | Bay 55-9837 acetate | 6α-Methylprednisolone 21-hemisuccinate sodium salt | Orforglipron | Tirzepatide Acetate(2023788-19-2 free base) | LSN3318839 |
| Related Compound Libraries | ReFRAME Related Library | NO PAINS Compound Library |
United States
